Allow several minutes for complete dissolution, checking visually to ensure no visible particles remain before use
The investigators reported improvements in skin density, dermal thickness, laxity (firmness), and reduction of fine lines in the GHK-Cu arm compared with vehicle control over the 12-week treatment period [3]
The FDAs decision was supported by the Phase III SUNLIGHT trial, where the LonsurfAvastin combination led to a median overall survival of 10.8 months versus 7.5 months on Lonsurf monotherapy, for a 39% reduction in risk of death
No, acne is not listed as a recognised adverse effect in the UK Summary of Product Characteristics for Mounjaro or in major clinical trial data from the SURPASS and SURMOUNT programmes
Next Steps for Centra Internal Medicine Patients For the most accurate and up-to-date pricing, we recommend: Contacting your preferred local pharmacy in Sun City for current pricing information